Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization by Pseudomonas bacteria including, for example, Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis are described.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

According to present invention embodiments, a trackable moiety can be attached to a quorum sensing (QS) molecule to form a QS modulating conjugate. QS modulating conjugates retain their activity for QS manipulation and are able to be detected by imaging techniques. The QS portion of the QS modulating conjugate can play a role in affecting bacterial behaviors, such as, inhibition of biofilms or disruption of toxin production, while the trackable moiety of the QS modulating conjugate enables monitoring, visualization in real time of its binding to the receptor on the bacterial surface, and the location of the bacterium itself, for example, in a biofilm and/or at an infection site. Since binding of the QS modulating conjugate to its cognate receptor is specific, the QS modulating conjugate can be used for diagnostic applications by enabling pinpointing of specific bacteria at infection sites.

A method of determining the P. aeruginosa or related species infection status of a subject comprising: (i) providing a sample of material obtained from the subject; (ii) determining the level of one or more alkyl quinolones or metabolites thereof produced by P. aeruginosa or a related species in the sample

A method for rapid differential diagnosis of infection using supercritical fluid chromatographic separation of quorum sensing molecules as biomarkers for infection agents.

The present invention relates to methods for identifying the presence or elevated levels of IgG2 specific for O-antigen of Gram-negative bacteria in a subject. The method comprises providing a binding agent specific for said IgG2, contacting the binding agent with the sample, allowing the binding agent and IgG2 to form a complex and thereafter directly or indirectly detecting the complex. Also provided are methods for assessing the severity of infection and/or a worsening of a patient's condition. The present invention also relates to isolated O-antigens.

Pharmaceutical extracts from Egyptian broomrape have proven efficacy against HCV and NAFLD. Compositions and method of making and using same are provided.

The present invention relates to a method for diagnosing a lung disease based on antibodies against microorganism-derived vesicles and, more particularly, to a method for diagnosing a lung disease by performing bacterial metagenome analysis using samples derived from a subject to analyze an increase or decrease in IgG, IgG1 and/or IgG4 levels in extracellular vesicles derived from specific bacteria.